ArticleTrials2026

A pragmatic trial with an optimized dose of rifampicin and moxifloxacin for the treatment of drug-susceptible pulmonary tuberculosis: a study protocol for open-label, randomized phase III trial (OptiRiMoxTB).

Hamu J Mlyuka et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.